Walker Jaqui, Cattaneo Marco, Badimon Lina, Agnelli Giancarlo, Chan Andrew T, Lanas Angel, Rocca Bianca, Rothwell Peter, Patrignani Paola, Langley Ruth, Vilahur Gemma, Cosentino Francesco
International Aspirin Foundation, 34 Bower Mount Road, Maidstone, Kent ME16 8AU, UK.
Medicina 2, ASST Santi Paolo e Carlo, Milan, Italy - Dipartimento di Science della Salute, Università degli studi di Milano, 20122 Milan, Italy.
Ecancermedicalscience. 2020 Jan 13;14:998. doi: 10.3332/ecancer.2020.998. eCollection 2020.
At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.
在2019年于意大利罗马举行的国际阿司匹林基金会科学会议“抗血栓治疗预防心血管疾病的益处与风险”上,国际专家们力求讨论和辩论心血管疾病(CVD)二级预防的最佳抗血栓策略,并就阿司匹林用于一级疾病预防的剂量和目标人群达成共识。获取最佳证据以支持临床实际决策可能很复杂,而个性化管理以平衡不同疾病预防策略的风险和益处似乎是最佳方法。希望未来的决策工具和生物标志物将有助于针对最可能受益的人群指导治疗。